表紙
市場調查報告書

惡性血液疾病檢驗的全球市場:分析與預測 (2019-2025年)

Global Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape - Analysis and Forecast, 2019-2025

出版商 BIS Research Inc. 商品編碼 917489
出版日期 內容資訊 英文 198 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
惡性血液疾病檢驗的全球市場:分析與預測 (2019-2025年) Global Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape - Analysis and Forecast, 2019-2025
出版日期: 2019年11月11日內容資訊: 英文 198 Pages
簡介

全球惡性血液疾病檢驗市場在2019年∼2025年間,預測將以15.24%的年複合成長率 (CAGR) 擴大。

本報告提供全球惡性血液疾病檢驗市場相關調查,世界市場規模與成長預測,各產品、疾病、技術、終端用戶、地區的分析與預測,競爭情形分析,及主要企業的簡介等系統性資訊。

摘要整理

第1章 市場定義

第2章 市場動態

  • 市場成長促進因素
  • 阻礙市場成長要素
  • 市場機會

第3章 競爭情形

  • 主要策略、發展
  • 產品方案
  • 資金籌措方案
  • 市場佔有率分析
  • 成長佔有率分析 (機會製圖)
  • 全面的競爭目錄

第4章 產業考察

  • 法律規範
  • 醫療費償付方案
  • 醫生的認識

第5章 全球惡性血液疾病檢驗市場:各產品

  • 服務
  • 套件

第6章 全球惡性血液疾病檢驗市場:各疾病

  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤
  • 骨髓增生性腫瘤
  • 骨髓發育不良症候群

第7章 全球惡性血液疾病檢驗市場:各技術

  • 次世代定序 (NGS)
  • 聚合酵素鏈鎖反應 (PCR)
  • 螢光原位雜交 (FISH)
  • 免疫組織染色 (IHC)
  • 流動化學
  • 其他技術

第8章 全球惡性血液疾病檢驗市場:各終端用戶

  • 專門診所、病因
  • 診斷實驗室
  • 索引實驗室
  • 研究機關

第9章 全球惡性血液疾病檢驗市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 其他 (RoW)

第10章 企業簡介

  • 概要
  • Abbott Laboratories
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Bio-Rad Laboratories, Inc.
  • Sysmex Corporation
  • ASURAGEN, INC.
  • Cancer Genetics Inc.
  • QIAGEN N.V.
  • ArcherDX, Inc.
  • Adaptive Biotechnologies
  • ICON plc
  • Quest Diagnostics Incorporated
  • ARUP Laboratories
  • Invivoscribe, Inc.
  • NeoGenomics Laboratories, Inc.

第11章 調查範圍、調查手法

目錄
Product Code: BH173A

Global Hematologic Malignancies Testing Market to Grow at a CAGR of 15.24% from 2019-2025

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global hematologic malignancies testing market?
  • What are the underlying structures resulting in the emerging trends within the global hematologic malignancies testing market?
  • How is each segment expected to grow in the global hematologic malignancies testing market during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2025?
  • What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in developed and developing regions for hematologic malignancies testing?
  • Who are the leading players with significant offerings to the global hematologic malignancies testing market? What is the current market dominance for each of these leading players?
  • What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2019-2025?
  • What are the key applications in global hematologic malignancies testing market? What are the major segments of these applications?
  • Which are the dominant disease areas of the global hematologic malignancies testing market? Which is the fastest growing disease area in the global hematologic malignancies testing market?
  • Who are the key manufacturers and service providers in the global hematologic malignancies testing market, and what are their contributions? What is the growth potential of each major hematologic malignancies testing solution provider?
  • What is the scope of the global hematologic malignancies testing market in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa?

Global Hematologic Malignancies Testing Market Forecast, 2019-2025

The hematologic malignancies testing industry analysis by BIS Research projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2025. The hematologic malignancies testing market generated $1,754.8 million revenue in 2018, in terms of value.

The hematologic malignancies testing market growth has been primarily attributed to the major drivers in this market such as rising incidence of hematologic malignancies, increasing adoption of inorganic growth strategies in the market, favorable reimbursement scenario in the global hematologic malignancies testing market, and increasing funding in hematologic malignancies testing market. However, there are significant challenges which are restraining the market growth. These challenges include high pricing pressure, lack of trained professionals, and issues pertaining to the analytical validity of genetic testing for cancers.

Expert Quote

"The development of specialized kits has achieved huge success over the past year with NGS and FISH based kits now available across major regions proving the potential to screen malignancies at an early stage."

Scope of the Market Intelligence on Hematologic Malignancies Testing Market

The hematologic malignancies testing market report provides a holistic view of the market in terms of various factors influencing it, including product optimization, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global hematologic malignancies testing market.

Market Segmentation

The hematologic malignancies testing market segmentation (on the basis of product) is further segmented into kits and services.

The hematologic malignancies testing market segmentation (on the basis of disease) is segmented into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndromes.

The hematologic malignancies testing market segmentation (on the basis of technology) is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC).

The hematologic malignancies testing market segmentation (on the basis of end user) is segmented into specialty clinics and hospitals, diagnostic laboratories, reference laboratories, and research institutions.

Key Companies in the Hematologic Malignancies Testing Market

The key manufacturers who have been contributing significantly to the Hematologic malignancies testing market include Abbott Laboratories, Adaptive Biotechnologies, ArcherDX, Inc., ARUP Laboratories, ASURAGEN, INC., Bio-Rad Laboratories, Inc., Cancer Genetics Inc., Sysmex Corporation, F. Hoffmann-La Roche AG, Illumina, Inc, Invivoscribe, Inc., Invitae Corporation, ICON plc, NeoGenomics Laboratories, Inc., and QIAGEN N.V., among others.

Table of Contents

Executive Summary

1 Market Overview

  • 1.1 Introduction
  • 1.2 Historical Perspective
  • 1.3 Types of Hematologic Malignancy Diagnostic Tests
  • 1.4 Global Footprint
  • 1.5 Trends and Future Potential

2 Market Dynamics

  • 2.1 Market Drivers
    • 2.1.1 Rising Incidence of Hematologic Malignancies
    • 2.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
    • 2.1.3 Favorable Reimbursement Scenario in the Global Hematologic Malignancies Testing Market
    • 2.1.4 Increase in Funding in Hematologic Malignancies Testing Market
  • 2.2 Restraints
    • 2.2.1 High Pricing Pressure
    • 2.2.2 Lack of Trained Professionals
    • 2.2.3 Issues Pertaining to the Analytical Validity of Genetic Testing for Cancers
  • 2.3 Market Opportunities
    • 2.3.1 Opportunities in the Emerging Economies
    • 2.3.2 Technological Advancements in the Field of Molecular Diagnostics

3 Competitive Landscape

  • 3.1 Key Strategies and Developments
    • 3.1.1 Synergistic Activities
    • 3.1.2 Approvals
    • 3.1.3 Product Launches and Enhancements
    • 3.1.4 Acquisitions
    • 3.1.5 Expansion Activities
  • 3.2 Product Scenario
  • 3.3 Funding Scenario
  • 3.4 Market Share Analysis
  • 3.5 Growth Share Analysis (Opportunity Mapping)
    • 3.5.1 By Company
    • 3.5.2 By Region
    • 3.5.3 By Product
  • 3.6 Comprehensive Competitive Index

4 Industry Insights

  • 4.1 Regulatory Framework
    • 4.1.1 Legal Requirements and Framework in the U.S.
    • 4.1.2 Legal Requirements and Framework in Europe
    • 4.1.3 Legal Requirements and Framework in Asia-Pacific
      • 4.1.3.1 Japan
      • 4.1.3.2 China
  • 4.2 Reimbursement Scenario
  • 4.3 Physicians' Perceptions

5 Global Hematologic Malignancies Testing Market (by Product)

  • 5.1 Services
  • 5.2 Kits
    • 5.2.1 Gene Panels
    • 5.2.2 Molecular Clonality Testing
    • 5.2.3 Translocation Testing
    • 5.2.4 Mutation Testing
    • 5.2.5 Minimal Residual Disease (MRD) Testing

6 Global Hematologic Malignancies Testing Market (by Disease)

  • 6.1 Leukemia
  • 6.2 Lymphoma
  • 6.3 Multiple Myeloma
  • 6.4 Myeloproliferative Neoplasms
  • 6.5 Myelodysplastic Syndromes

7 Global Hematologic Malignancies Testing Market (by Technology)

  • 7.1 Next-Generation Sequencing (NGS)
  • 7.2 Polymerase Chain Reaction (PCR)
  • 7.3 Fluorescence in Situ Hybridization (FISH)
  • 7.4 Immunohistochemistry (IHC)
  • 7.5 Flow Cytometry
  • 7.6 Other Technologies

8 Global Hematologic Malignancies Testing Market (by End User)

  • 8.1 Specialty Clinics and Hospitals
  • 8.2 Diagnostic Laboratories
  • 8.3 Reference Laboratories
  • 8.4 Research Institutions

9 Global Hematologic Malignancies Testing Market (by Region)

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Rest-of-Europe
  • 9.4 Asia-Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 Singapore
    • 9.4.6 Rest-of-APAC
  • 9.5 Rest-of-the-World
    • 9.5.1 Latin America
    • 9.5.2 Middle East and Africa

10 Company Profiles

  • 10.1 Overview
  • 10.2 Abbott Laboratories
    • 10.2.1 Company Overview
    • 10.2.2 Role of Abbott Laboratories in the Global Hematologic Malignancies Testing Market
    • 10.2.3 Financials
    • 10.2.4 Key Insights About Financial Health of the Company
    • 10.2.5 SWOT Analysis
  • 10.3 Illumina, Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Role of Illumina, Inc. in the Global Hematologic Malignancies Testing Market
    • 10.3.3 Financials
    • 10.3.4 Key Insights About Financial Health of the Company
    • 10.3.5 SWOT Analysis
  • 10.4 F. Hoffmann-La Roche Ltd
    • 10.4.1 Company Overview
    • 10.4.2 Role of F. Hoffmann-La Roche Ltd in the Global Hematologic Malignancies Testing Market
    • 10.4.3 Financials
    • 10.4.4 Key Insights About Financial Health of the Company
    • 10.4.5 SWOT Analysis
  • 10.5 Bio-Rad Laboratories, Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Role of Bio-Rad Laboratories, Inc. in the Global Hematologic Malignancies Testing Market
    • 10.5.3 Financials
    • 10.5.4 Key Insights About Financial Health of the Company
    • 10.5.5 SWOT Analysis
  • 10.6 Sysmex Corporation
    • 10.6.1 Company Overview
    • 10.6.2 Role of Sysmex Corporation in the Global Hematologic Malignancies Testing Market
    • 10.6.3 Financials
    • 10.6.4 Key Insights About Financial Health of the Company
    • 10.6.5 SWOT Analysis
  • 10.7 ASURAGEN, INC.
    • 10.7.1 Company Overview
    • 10.7.2 Role of ASURAGEN, INC. in the Global Hematologic Malignancies Testing Market
    • 10.7.3 SWOT Analysis
  • 10.8 Cancer Genetics Inc.
    • 10.8.1 Company Overview
    • 10.8.2 Role of Cancer Genetics Inc.in the Global Hematologic Malignancies Testing Market
    • 10.8.3 Financials
    • 10.8.4 Key Insights About Financial Health of the Company
    • 10.8.5 SWOT Analysis
  • 10.9 QIAGEN N.V.
    • 10.9.1 Company Overview
    • 10.9.2 Role of QIAGEN N.V. in the Global Hematologic Malignancies Testing Market
    • 10.9.3 Financials
    • 10.9.4 Key Insights about Financial Health of the Company
    • 10.9.5 SWOT Analysis
  • 10.10 ArcherDX, Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Role of ArcherDX, Inc. in the Global Hematologic Malignancies Testing Market
    • 10.10.3 SWOT Analysis
  • 10.11 Adaptive Biotechnologies
    • 10.11.1 Company Overview
    • 10.11.2 Role of Adaptive Biotechnologies in the Global Hematologic Malignancies Testing Market
    • 10.11.3 SWOT Analysis
  • 10.12 ICON plc
    • 10.12.1 Company Overview
    • 10.12.2 Role of ICON plc in the Global Hematologic Malignancies Testing Market
    • 10.12.3 Financials
    • 10.12.4 SWOT Analysis
  • 10.13 Quest Diagnostics Incorporated
    • 10.13.1 Company Overview
    • 10.13.2 Role of Quest Diagnostics Limited in the Global Hematologic Malignancies Testing Market
    • 10.13.3 Financials
    • 10.13.4 SWOT Analysis
  • 10.14 ARUP Laboratories
    • 10.14.1 Company Overview
    • 10.14.2 Role of ARUP Laboratories in the Global Hematologic Malignancies Testing Market
    • 10.14.3 SWOT Analysis
  • 10.15 Invivoscribe, Inc.
    • 10.15.1 Company Overview
    • 10.15.2 Role of Invivoscribe, Inc. in the Global Hematologic Malignancies Testing Market
    • 10.15.3 SWOT Analysis
  • 10.16 NeoGenomics Laboratories, Inc.
    • 10.16.1 Company Overview
    • 10.16.2 Role of NeoGenomics Laboratories, Inc. in the hematologic malignancies testing Market
    • 10.16.3 Financials
    • 10.16.4 Key Insights about Financial Health of the Company
    • 10.16.5 SWOT Analysis

11 Research Scope and Methodology

  • 11.1 Scope of the Study
  • 11.2 Research Methodology
  • 11.3 Data Sources
  • 11.4 Assumptions and Limitations
  • 11.5 Data and Prediction Modeling

List of Tables

  • Table 1.1: Global Hematologic Malignancies Testing Market, by Region, 2018-2025 ($Million)
  • Table 3.1: Market Players with Key Product Listing
  • Table 4.1: Registration Criteria for IVD Medical Devices as per the CFDA
  • Table 4.2: Key Coverage Providers for Hematologic Malignancies Testing

List of Figures

  • Figure 1: Impact Analysis on the Global Hematologic Malignancies Testing Market
  • Figure 2: Hematologic Malignancies Testing Market, By Product, 2018 vs. 2025 ($Million)
  • Figure 3: Hematologic Malignancies Testing Market, By Disease, 2018 vs. 2025 ($Million)
  • Figure 4: Hematologic Malignancies Testing Market, By End User, 2018 vs. 2025 ($Million)
  • Figure 5: Global Hematologic Malignancies Testing Market Snapshot
  • Figure 1.1: Global Hematologic Malignancies Testing Market, 2018-2025 ($Million)
  • Figure 2.1: Market Dynamics of Global Hematologic Malignancies Testing Market
  • Figure 2.2: Leukemia, U.S. Incident Rates per 100,000, 2006-2015
  • Figure 3.1: Share of Key Developments and Strategies, January 2016 - September 2019
  • Figure 3.2: Synergistic Activities Share (by Companies), January 2016 - September 2019
  • Figure 3.3: Approvals Share (by Companies), January 2016 - September 2019
  • Figure 3.4: Product Launches and Enhancements Share (by Companies), January 2016 - September 2019
  • Figure 3.5: Acquisition and Merger Share (by Companies), January 2016 - September 2019
  • Figure 3.6: Market Share Analysis for the Global Hematologic Malignancies Testing Market, 2018
  • Figure 3.7: Growth Share Matrix for Global Hematologic Malignancies Testing Market (by company), 2018
  • Figure 3.8: Growth Share Matrix for Global Hematologic Malignancies Testing Market (by region), 2018
  • Figure 3.9: Growth Share Matrix for Global Hematologic Malignancies Testing Market (by Product), 2018
  • Figure 3.10: Comprehensive Competitive Index, 2018 (by Region)
  • Figure 5.1: Global Hematologic Malignancies Testing Market (by Product), 2019 vs 2025
  • Figure 5.2: Hematologic Malignancies Testing Services Market, $Million, 2018-2025
  • Figure 5.3: Hematologic Malignancies Testing Kits Market, $Million, 2018-2025
  • Figure 5.4: Gene Panels Market, $Million, 2018-2025
  • Figure 5.5: Molecular Clonality Testing Market, $Million, 2018-2025
  • Figure 5.6: Translocation Testing Market, $Million, 2018-2025
  • Figure 5.7: Mutation Testing Market, $Million, 2018-2025
  • Figure 5.8: Minimal Residual Disease (MRD) Testing Market, $Million, 2018-2025
  • Figure 6.1: Global Hematologic Malignancies Testing Market (by Disease), 2019 vs 2025
  • Figure 6.2: Leukemia Testing Market, $Million, 2018-2025
  • Figure 6.3: Lymphoma Testing Market, $Million, 2018-2025
  • Figure 6.4: Multiple Myeloma Testing Market, $Million, 2018-2025
  • Figure 6.5: Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
  • Figure 6.6: Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
  • Figure 7.1: Global Hematologic Malignancies Testing Market (by Technology), 2019 vs 2025
  • Figure 7.2: Hematologic Malignancies Testing Market by NGS, $Million, 2018-2025
  • Figure 7.3: Hematologic Malignancies Testing Market by PCR, $Million, 2018-2025
  • Figure 7.4: Hematologic Malignancies Testing Market by FISH, $Million, 2018-2025
  • Figure 7.5: Hematologic Malignancies Testing Market by Immunohistochemistry, $Million, 2018-2025
  • Figure 7.6: Hematologic Malignancies Testing Market by Flow Cytometry, $Million, 2018-2025
  • Figure 7.7: Hematologic Malignancies Testing Market by Other Technologies, $Million, 2018-2025
  • Figure 8.1: Global Hematologic Malignancies Testing Market (by End User), 2019 vs 2025
  • Figure 8.2: Specialty Clinics and Hospitals Market, $Million, 2018-2025
  • Figure 8.3: Diagnostic Laboratories Market, $Million, 2018-2025
  • Figure 8.4: Reference Laboratories Market, $Million, 2018-2025
  • Figure 8.5: Research Institutions Market, $Million, 2018-2025
  • Figure 9.1: Hematologic Malignancies Testing Market (by Region), $Million, 2019 and 2025
  • Figure 9.2: North America: Market Dynamics
  • Figure 9.3: North America Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.4: North America Hematologic Malignancies Testing Market (by Country), $Million, 2019 vs 2025
  • Figure 9.5: U.S. Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.6: Canada Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.7: Europe: Market Dynamics
  • Figure 9.8: Europe Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.9: Europe Hematologic Malignancies Testing Market (by Country), $Million, 2019 vs 2025
  • Figure 9.10: Germany Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.11: U.K. Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.12: France Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.13: Italy Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.14: Spain Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.15: Rest-of-Europe Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.16: Asia-Pacific: Market Dynamics
  • Figure 9.17: Asia-Pacific Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.18: Asia-Pacific Hematologic Malignancies Testing Market (by Country), $Million, 2019 vs 2025
  • Figure 9.19: China Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.20: Japan Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.21: India Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.22: Number of Death in India, by Leukemia (2010-2017)
  • Figure 9.23: Australia Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.24: Number of Death in Australia, by Leukemia (2010-2017)
  • Figure 9.25: Singapore Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.26: Rest-of-APAC Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.27: Rest-of-the-World: Market Dynamics
  • Figure 9.28: Rest-of-the-World Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.29: Rest-of-the-World Hematologic Malignancies Testing Market (by Country), $Million, 2019 vs 2025
  • Figure 9.30: Latin America Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.31: Middle East and Africa Hematologic Malignancies Testing Market, $Million, 2018-2025
  • Figure 9.32: Cancer Deaths in Saudi Arabia, By Type (2010-2016)
  • Figure 10.1: Total Number of Companies Profiled
  • Figure 10.2: Abbott Laboratories: Overall Product Portfolio
  • Figure 10.3: Abbott Laboratories: Overall Financials, 2016-2018
  • Figure 10.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
  • Figure 10.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
  • Figure 10.6: Abbott Laboratories: Revenue (by Region), 2016-2018
  • Figure 10.7: Abbott Laboratories: R&D Expenditure, 2016-2018
  • Figure 10.8: Abbott Laboratories: SWOT Analysis
  • Figure 10.9: Illumina, Inc.: Overall Product Portfolio
  • Figure 10.10: Illumina, Inc.: Overall Financials, 2016-2018
  • Figure 10.11: Illumina, Inc.: Revenue (by Segment), 2016-2018
  • Figure 10.12: Illumina, Inc.: Revenue (by Region), 2016-2018
  • Figure 10.13: Illumina, Inc.: R&D Expenditure, 2016-2018
  • Figure 10.14: Illumina, Inc.: SWOT Analysis
  • Figure 10.15: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 10.16: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
  • Figure 10.17: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2016-2018
  • Figure 10.18: F. Hoffmann-La Roche Ltd: Sales (by Region), 2016-2018
  • Figure 10.19: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
  • Figure 10.20: F. Hoffmann-La Roche: SWOT Analysis
  • Figure 10.21: Bio-Rad Laboratories, Inc.: Product Portfolio
  • Figure 10.22: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
  • Figure 10.23: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2016-2018
  • Figure 10.24: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018
  • Figure 10.25: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
  • Figure 10.26: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 10.27: Sysmex Corporation: Overall Product Portfolio
  • Figure 10.28: Sysmex Corporation: Overall Financials, 2016-2018
  • Figure 10.29: Sysmex Corporation: Sales (by Segment), 2016-2018
  • Figure 10.30: Sysmex Corporation: Sales (by Region), 2016-2018
  • Figure 10.31: Sysmex Corporation: R&D Expenditure, 2016-2018
  • Figure 10.32: Sysmex Corporation: SWOT Analysis
  • Figure 10.33: ASURAGEN, INC.: Overall Product Portfolio
  • Figure 10.34: ASURAGEN, INC.: SWOT Analysis
  • Figure 10.35: Product Portfolio: Cancer Genetics Inc.
  • Figure 10.36: Cancer Genetics Inc.: Overall Financials, 2016-2018
  • Figure 10.37: Cancer Genetics Inc.: Sales (by Segment), 2016-2018
  • Figure 10.38: Cancer Genetics Inc.: Sales (by Region), 2016-2018
  • Figure 10.39: Cancer Genetics Inc.: R&D Expenditure, 2016-2018
  • Figure 10.40: Cancer Genetics Inc.: SWOT Analysis
  • Figure 10.41: QIAGEN N.V.: Overall Product Portfolio
  • Figure 10.42: QIAGEN N.V.: Overall Financials, 2016-2018
  • Figure 10.43: QIAGEN N.V.: Revenue (by Segment), 2016-2018
  • Figure 10.44: QIAGEN N.V.: Revenue (by Region), 2016-2018
  • Figure 10.45: QIAGEN N.V.: R&D Expenditure, 2016-2018
  • Figure 10.46: QIAGEN N.V.: SWOT Analysis
  • Figure 10.47: ArcherDX, Inc.: Overall Product Portfolio
  • Figure 10.48: ArcherDX, Inc.: SWOT Analysis
  • Figure 10.49: Adaptive Biotechnologies: Overall Product Portfolio
  • Figure 10.50: Adaptive Biotechnologies: SWOT Analysis
  • Figure 10.51: ICON plc: Overall Product Portfolio
  • Figure 10.52: ICON plc: Overall Financials, 2016-2018
  • Figure 10.53: ICON plc: Revenue (by Region), 2016-2018
  • Figure 10.54: ICON plc: SWOT Analysis
  • Figure 10.55: Quest Diagnostics Incorporated: Overall Product Portfolio
  • Figure 10.56: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
  • Figure 10.57: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2016-2018
  • Figure 10.58: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 10.59: ARUP Laboratories: Overall Product Portfolio
  • Figure 10.60: ARUP Laboratories: SWOT Analysis
  • Figure 10.61: Invivoscribe, Inc.: Overall Product Portfolio
  • Figure 10.62: Invivoscribe, Inc.: SWOT Analysis
  • Figure 10.63: NeoGenomics Laboratories, Inc.: Overall Product Portfolio
  • Figure 10.64: NeoGenomics Laboratories, Inc.: Overall Financials, 2016-2018
  • Figure 10.65: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2016-2018
  • Figure 10.66: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2016-2018
  • Figure 10.67: NeoGenomics Laboratories, Inc.: SWOT Analysis
  • Figure 11.1: Global Hematologic Malignancies Testing Market Segmentation
  • Figure 11.2: Global Hematologic Malignancies Testing Market Research Methodology
  • Figure 11.3: Primary Research
  • Figure 11.4: Secondary Research
  • Figure 11.5: Data Triangulation
  • Figure 11.6: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 11.7: Top-Down Approach (Segment-Wise Analysis)
  • Figure 11.8: Assumptions and Limitations
  • Figure 11.9: Considered Factors for Data Prediction and Modelling
Back to Top